Fragile X Syndrome is the leading cause of inherited mental illness, ranging from learning disabilities to more severe cognitive or intellectual disabilities, including autism. Connecticut pharmaceutical company Marinus, Inc. has developed the synthetic neurosteroid Ganaxolone for the treatment of Fragile X Syndrome (FXS), epilepsy, and Post-Traumatic Stress Disorder (PTSD). Now researchers at UC Davis have been awarded a $3 Million molecular biology research grant by the Department of Defense to study the effects of the drug on FXS specifically.
Ganaxolone is the synthetic analog of the neurosteroid allopregnanolone, a metabolite of progesterone. Unlike natural steroids, Maurinus' drug does not seem to produce classical hormonal side effects. Clinical trials for the use of ganaxalone in PTSD are also being funded by the DoD, with results due in 2012.
(Photo of Sacramento campus courtesy of UCDHS)
If you are a supplier of molecular biology research laboratory equipment, a researcher, purchaser, or lab manager, come to Biotechnology Calendar's Sacramento BioResearch Product Faire™ Event this June 15 on the UC Davis Campus in Sacramento.